tradeMONSTER: Trade free for 90 days

Options Trading News

October 2, 2013  Wed 8:11 AM CT

CELG: SEE CHART GET CHAIN FIND STRATEGIES
Celgene and Merck are crosstown rivals. One's always innovating, putting money to work in a variety of biotechs, buying when the time is right. It's always going for the blockbuster, trying to press, press, press.

The other is trying to cut its way to success by firing, trimming, and hoping to eke out money as its new products fail to ignite or just fail. It's unoriginal and staid--just trying to pay that dividend.

The first is obviously Celgene, and the second is Merck, which managed to pop its stock with an announcement that is laying off a bunch of people. It's a second reduction in force for this obviously bloated company.

TheStreet.com logoBut the first used to be Merck. It used to be the ultimate in original thinking and new products. Not anymore. Even its acquisition of the gigantic Schering-Plough in 2009 seems to have gotten it nothing significant that I can see. I had hoped that at least the company would follow in the footsteps of Pfizer and spin off animal health, but even that is apparently too radical.

Either way, I think that Merck's a sell, not a buy. The market wants growth and new drugs. If it wants yield, it can get it from Con Ed. Disappointing, again.

Disclosures:
Cramer's charitable trust has no positions in the stocks mentioned.
Share this article with your friends


Related Stories

CELG

Cramer: The winners just don't stop

December 3, 2014

The end-of-the-year phenomenon is working, and all you need to do look at longtime favorite names to see how this game works.

Invest Like a Monster - Las Vegas: March 13-14

Premium Services

Archived Webinar

The Art of Trading: Forgiving the Spread

Education & Strategy

Know thy Greeks!

One of the most important roles played by the Option Pricing Model is the calculation of an important family of...

View more education articles »
optionMONSTER stockMONSTER tradeMONSTER